[Monoclonal antibodies improve therapy of relapsing multiple sclerosis. Molecular basis and clinical results of anti-VLA4 (natalizumab) therapy].
Gold
R
R
Institut für MS-Forschung, Bereich Humanmedizin der Universität Göttingen und Gemeinnützige Hertie-Stiftung, Göttingen. r.gold@med.uni-goettingen.de
Hartung
H-P
HP
Hohlfeld
R
R
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D039041:Integrin alpha4beta1 / Q000235:genetics / Q000276:immunology* / Q000502:physiology; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000235:genetics; D000069442:Natalizumab; D012008:Recurrence
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D039041:Integrin alpha4beta1; D000069442:Natalizumab